Current Report Filing (8-k)
April 14 2017 - 5:29PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Pursuant
to
Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported) April 10, 2017
PRESSURE
BIOSCIENCES, INC.
(Exact
Name of Registrant as Specified in its Charter)
MASSACHUSETTS
(State
or Other Jurisdiction of Incorporation)
000-21615
|
|
04-2652826
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
14
Norfolk Avenue, South Easton, MA
|
|
02375
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(508)
230-1828
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
April 10, 2017, Mr. Joseph L. Damasio Jr. joined Pressure BioSciences, Inc. (the “Company”) as its Vice President
of Finance and Chief Financial Officer (“CFO”).
Mr.
Damasio, age 42, has 20 years of finance and accounting experience, most recently as Finance Director of Nelipak Corporation.
Prior to Nelipak Corporation, Mr. Damasio held various financial positions at CP Bourg, IQE, and Kopin Corporation. Prior to Kopin
Corporation, Mr. Damasio was employed for 6 years by the Company, first as Controller and later as Vice President of Finance &
Administration. Mr. Damasio became a CPA in 2003, and earned a B.S.B.A. in accounting from the University of Massachusetts and
an MBA from Boston College.
Family
Relationships
There
are no family relationships between Mr. Damasio and any other executive officer or member of the board of directors of the Company.
Related
Party Transactions
There
are no related party transactions with regard to Mr. Damasio reportable under Item 404(a) of Regulation S-K except that, since
January 1, 2016, the Company has paid Mr. Damasio $44,000 for his services as a financial consultant.
Material
Plans, Contracts, or Arrangements
In
connection with Mr. Damasio’s appointment as the Company’s Vice President of Finance and CFO, Mr. Damasio will be
paid an annual salary of $170,000. After one year of service, if Mr. Damasio is terminated without cause, he will be entitled
to receive severance in an amount equal to one year base salary, plus medical benefits. Effective immediately on date of hire,
if Mr. Damasio is terminated due to change of control, he will be entitled to receive severance in an amount equal to one year
base salary, plus medical benefits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Dated:
April 14, 2017
|
PRESSURE
BIOSCIENCES, INC.
|
|
|
|
|
|
|
By:
|
/s/
Richard T. Schumacher
|
|
|
Richard
T. Schumacher,
|
|
|
President
and Chief Executive Officer
|
Pressure Biosciences (QB) (USOTC:PBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pressure Biosciences (QB) (USOTC:PBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024